Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
- Written by PR Newswire
![]() |
BEIJING, SHANGHAI and BOSTON, Dec. 16, 2022 /PRNewswire/ -- Jacobio Pharma (1167. HK) announced that the Company's in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation...